Sign In
Buy CASBF
$2.86
+0 (+0%)
At Close: Jun 22, 2026
CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines
08:03am, Monday, 09'th Feb 2026
DUBAI, Feb. 9, 2026 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO"; SSE: 688185, HKEX: 06185) has been invited to share the practices of innovative vaccine at the World Government Summit 2026 (W
CanSino Biologics CEO on earnings, business outlook, and international partnerships
04:21am, Wednesday, 30'th Apr 2025
Yu Xuefeng, CEO of Chinese vaccine company CanSino Biologics, says the company remains on-track to breakeven in 2025, and remains committed to expanding into the global market. He also says the impact
Riding Covid Vaccine Highs, CanSino Plans Swiss Listing
06:49am, Tuesday, 17'th Jan 2023
After successful listings in Shanghai and Hong Kong, vaccine maker CanSino is preparing to move into Europe with a listing in Switzerland. Sales could surge for the company's Covid-19 vaccines as Chin
China 'Definitely' Needs 2nd Covid Booster Dose: CanSino Biologics CEO
11:47pm, Tuesday, 06'th Dec 2022
Yu Xuefeng, chief executive officer of CanSino Biologics Inc., a Tianjin, China-based drugmaker that's rolling out a vaccine that can be inhaled, discusses the supply-demand outlook in the country.
Why Is CanSino Biologics (CASBF) Stock Soaring Today?
02:34pm, Wednesday, 02'nd Nov 2022
CanSino Biologics (OTCMKTS: CASBF ) are ripping higher on Wednesday, with CASBF stock up about 75% on the day. The move is startling, particularly given the poor price action we were seeing in the ove
China's CanSinoBIO H1 revenue drops on weaker COVID shot demand
09:05pm, Sunday, 28'th Aug 2022
China's CanSino Biologics reported a 69.5% drop in revenue for the first six months versus a year ago, joining global and domestic COVID-19 vaccine makers affected by waning demand for their shots.
COVID shot drives CanSinoBIO's first six-month profit since at least 2019
10:10am, Friday, 27'th Aug 2021
Chinese vaccine maker CanSino Biologics Inc (CanSinoBIO) said on Friday it had returned to operating profit of 802.3 million yuan ($123.79 million) in the first six months of 2021, driven by use of it
Pandemic Accelerates China's Drive Into mRNA Treatments
11:23am, Friday, 18'th Jun 2021
Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases. High efficacy rates in preventing Covid-19 spark rush by Chinese compan
